With 2022 rapidly coming to a close (how? I’m still in 2020), the Neural Stem Cell Institute (NSCI) is reflecting on what a terrific year it has been for the institute and its hard-working team. Join us in celebrating the many accomplishments we have achieved this year! We will be posting updates …
clinical trial
NSCI IND Allowance for AMD Clinical Trial
NSCI is pleased to announce our successful IND application to the FDA that will enable clinical testing of a novel stem cell therapy for patients with age-related macular degeneration (AMD). In AMD, the retinal pigment epithelial cells (RPE) at the back of the eye degenerate, causing loss of …